Estimating HIV incidence and detection rates from surveillance data

Epidemiology

Volumn 15, Issue 2, 2004, Pages 164-172

  Posner, Stephanie J ^a,c   Myers, Leann ^b   Hassig, Susan E ^b   Rice, Janet C ^b   Kissinger, Patricia ^b   Farley, Thomas A ^b  

^a Louisiana Office of Public Health   (United States)

^b TULANE UNIVERSITY   (United States)

^c c/o PHRplus ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEMOGRAPHY; DIAGNOSTIC ACCURACY; EPIDEMIC; EXPOSURE; FEMALE; HEALTH SURVEY; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED STATES; METHODOLOGY; PROBABILITY;

FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LOUISIANA; MALE; MARKOV CHAINS; POPULATION SURVEILLANCE;

EID: 2442536088     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000112215.19764.2b     Document Type: Article

References (53)

1. Fleming PL, Wortley PM, Karon JM, et al. Tracking the HIV epidemic: current issues, future challenges. Am J Public Health. 2000;90:1037-1041.
2. HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control and Prevention; 1999:11.
3. Gail MH, Brookmeyer R. Methods for projecting course of acquired immunodeficiency syndrome epidemic. J Natl Cancer Inst. 1988;80:900-911.
4. Bacchetti P, Segal MR, Jewell NP. Backcalculation of HIV infection rates. Stat Sci. 1993;8:82-119.
5. Rosenberg PS, Gail MH, Carroll RJ. Estimating HIV prevalence and projecting AIDS incidence in the US: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med. 1992;11:1633-1655.
6. Marion SA, Schechter MT. Use of backcalculation for estimation of the probability of progression from HIV infection to AIDS. Stat Med. 1993;12:617-631.
7. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science. 1995;270:1372-1375.
8. Rosenberg PS. Backcalculation models of age-specific HIV incidence rates. Stat Med. 1994;13:1975-1990.
9. Mariotti S, Cascioli R. Sources of uncertainty in estimating HIV infection rates by back-calculation: an application to Italian data. Stat Med. 1996;15:2669-2687.
10. Rosenberg PS, Gail MH. Uncertainty in estimates of HIV prevalence derived by backcalculation. Ann Epidemiol. 1990;1:105-115.
11. Rosenberg PS, Gail MH. Backcalculation of flexible linear models of the human immunodeficiency virus infection curve. App Stats. 1991;40:269-282.
12. Marschner IC. Using time of first positive test and other auxiliary data in back projection of AIDS incidence. Stat Med. 1994;13:1959-1974.
13. Motika M, Becker NG, Wylie B, et al. Non-parametric analysis of transfusion-related HIV and AIDS incidence data. Stat Med. 1994;13:2043-2058.
14. Aalen OO, Farewell VT, De Angelis D, et al. The use of human immunodeficiency virus diagnosis information in monitoring the acquired immune deficiency syndrome epidemic. J R Stat Soc. 1994;A157:3-16.
15. Raab GM, Fielding KL, Allardice G. Incorporating HIV test data into forecasts of the AIDS epidemic in Scotland. Stat Med. 1994;13:2009-2020.
16. Amundsen EJ, Aalen OO, Stigum H, et al. Back-calculation based on HIV and AIDS registers in Denmark, Norway and Sweden 1977-1995 among homosexual men: estimation of absolute rates, incidence rates and prevalence of HIV. J Epidemiol Biostat. 2000;5:233-243.
17. Aalen OO, Farewell VT, De Angelis D, et al. A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales. Stat Med. 1997;16:2191-2210.
18. Dietz K, Seydel J, Schwartlander B. Back-projection of German AIDS data using information on dates of tests. Stat Med. 1994;13:1991-2008.
19. Blaxhult A, Svensson A. Assessing the extent of the HIV epidemic in Sweden, using information on the extent to which people who develop AIDS are already known to be HIV infected. Int J Epidemiol. 1992;21:784-791.
20. Farewell VT, Aalen OO, DeAngelis D, et al. Estimation of the rate of diagnosis of HIV infection in HIV infected individuals. Biometrika. 1994;81:287-294.
21. Satten GA, Longini IM. Estimation of incidence of HIV infection using cross-sectional marker surveys. Biometrics. 1994;50:675-688.
22. Longini IMJr, Clark WS, Gardner LI, et al. The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr. 1991;4:1141-1147.
23. Longini IM, Clark WS, Haber M, et al. The stages of HIV infection: Waiting times and infection transmission probabilities. In: Castillo-Chavez C, ed. Lecture Notes in Biomathematics (83). Berlin: Springer-Verlag; 1989.
24. Longini IM. Modeling the decline of CD4+ T-lymphocyte counts in HIV-infected individuals. J Acquir Immune Defic Syndr. 1990;3:930-931.
25. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17).
26. Longini IM, Clark WS, Karon JM. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. Am J Epidemiol. 1993;137:1229-1240.
27. Becker NG, Marschner IC. A method for estimating the age-specific relative HIV infection from AIDS incidence data. Biometrika. 1993;80:165-178.
28. Aalen OO, Farewell VT, De Angelis D, et al. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS. 1999;13:103-108.
29. Graham NM, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr. 1991;4:267-276.
30. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and PCP prophylaxis on progression of HIV-1 infection to AIDS. Lancet. 1991;338:265-269.
31. Weidle PJ, Holmberg SD, DeCock KM. Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy. AIDS. 1993;13(suppl A):S61-S68.
32. Brundage JF, McNeil JG, Miller RN, et al. The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infection: estimates based on the experience of the US Army. J Acquir Immune Defic Syndr. 1990;3:92-94.
33. Zierler S. Efficacy vs. impact of human immunodeficiency virus-related drug therapies. Epidemiology. 1998;9:590-593.
34. Weller IVD. The impact of antiviral therapy on HIV disease. In: Dalgleish AG, Weiss RA, eds. HIV and the New Viruses. San Diego: Academic Press; 1999.
35. Alioum A, Leroy V, Commenges D, et al. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Epidemiology. 1998;9:605-612.
36. Longini IMJr, Byers RH, Hessol NA, et al. Estimating the stage-specific numbers of HIV infection using a Markov model and back-calculation. Stat Med. 1992;11:831-843.
37. Satten GA, Longini IM. Markov chains with measurement error: Estimating the 'true' course of a marker of the progression of HIV disease. App Stats. 1996;45:275-309.
38. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-1090.
39. van Haastrecht HJA, van den Hoek AAR, Coutinho RA. High mortality among HIV-infected injecting drug users without AIDS diagnosis: implications for HIV infection epidemic modelers? AIDS. 1994;8:363-366.
40. Hendriks JC, Satten GA, Longini IM, et al. Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men. AIDS. 1996;10:649-656.
41. Green TA. Using surveillance data to monitor trends in the AIDS epidemic. Stat Med. 1998;17:143-154.
42. HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control and Prevention; 1996:8.
43. Louisiana Office of Public Health, HIV/AIDS Program. 1996 Louisiana HIV/AIDS Surveillance Report. New Orleans: HIV/AIDS Program; 1997.
44. Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997. MMWR Morb Mortal Wkly Rep. 1999;48:45-48.
45. Centers for Disease Control and Prevention. Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-1999. MMWR Morb Mortal Wkly Rep. 1999;48:773-777.
46. Wortley PM, Lindegren ML, Fleming PL. Successful implementation of perinatal HIV prevention guidelines. MMWR Morb Mortal Wkly Rep. 2001;50:15-28.
47. Rosenberg PS, Goedert JJ, Biggar RJ. Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. AIDS. 1994;8:803-810.
48. Hendriks JC, Craib KJ, Veugelers PJ, et al. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model. Int J Epidemiol. 2000;29:565-572.
49. Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS. 1990;4:1059-1066.
50. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS. 1997;11(suppl A):S69-76.
51. Hessol NA, Palacio H. Gender, ethnicity and transmission category variation in HIV disease progression. AIDS. 1996;10(suppl A):S69-74.
52. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol. 1994;139:1077-1087.
53. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.